vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2013-2-109-112vtio-104Research ArticleКлинические наблюденияClinical CasesТЯЖЕЛАЯ ИММУННАЯ ГЕМОЛИТИЧЕСКАЯ АНЕМИЯ ПОСЛЕ ТРАНСПЛАНТАЦИИ ПЕЧЕНИSEVERE IMMUNE HEMOLYTIC ANEMIA AFTER LIVER TRANSPLANTATIONСушковА. И.SushkovA. I.МалиновскаяЮ. О.MalinovskayaY. O.МилосердовИ. А.MiloserdovI. A.МойсюкЯ. Г.MoysyukY. G.Отделение трансплантации печени и почки (зав. – проф. Я.Г. Мойсюк) ФГБУ «ФНЦ трансплантологии и искусственных органов им. акад. В.И. Шумакова» Минздрава России (директор – академик РАМН, проф. С.В. Готье), Москва, Российская ФедерацияLiver and Kidney transplantation division (Head – prof. Y.G. Moysyuk) Academician V.I. Schumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of the Russian Federation (Head – academician of RAMSci, prof. S.V. Gautier) Moscow, Russian FederationОтделение трансплантации печени и почки (зав. – проф. Я.Г. Мойсюк) ФГБУ «ФНЦ трансплантологии и искусственных органов им. акад. В.И. Шумакова» Минздрава России (директор – академик РАМН, проф. С.В. Готье), Москва, Российская Федерация Кафедра трансплантологии и искусственных органов (зав. – академик РАМН, проф. С.В. Готье) ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» (ректор – член-корр. РАМН, проф. П.В. Глыбочко), Москва, Российская ФедерацияLiver and Kidney transplantation division (Head – prof. Y.G. Moysyuk) Academician V.I. Schumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of the Russian Federation (Head – academician of RAMSci, prof. S.V. Gautier) Moscow, Russian Federation Department of Transplantology and Artificial organs (Head – academician of RAMSci, prof. S.V. Gautier) I.M. Sechenov First Moscow State Medical University (Rector – corresponding member of RAMSci, prof. P.V. Glybochko), Moscow, Russian Federation201316052014152ВЕСТНИК ТРАНСПЛАНТОЛОГИИ И ИСКУССТВЕННЫХ ОРГАНОВ том XV No 2–2013109112Copyright © Сушков А.И., Малиновская Ю.О., Милосердов И.А., Мойсюк Я.Г., 20132013Сушков А.И., Малиновская Ю.О., Милосердов И.А., Мойсюк Я.Г.Sushkov A.I., Malinovskaya Y.O., Miloserdov I.A., Moysyuk Y.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/104

В статье представлен клинический случай успешного излечения тяжелой иммунной гемолитической ане- мии у пациента после трансплантации печени. Причиной развития осложнения явился так называемый синдром лимфоцитов-пассажиров (разновидность реакции «трансплантат против хозяина»). Проведение двух сеансов плазмафереза и внутривенное введение человеческого иммуноглобулина в дозе 0,5 г/кг в сочетании с усилением поддерживающей иммуносупрессии кратким курсом перорального приема ме- тилпреднизолона в суммарной дозе 150 мг в течение 12 дней оказались эффективными. Пациент выписан из клиники через 34 дня после трансплантации в удовлетворительном состоянии со стабильным уровнем гемоглобина. 

Clinical case of successful treatment of severe immune hemolytic anemia after liver transplantation is represen- ted in this article. The cause of complication was so-called passenger lymphocyte syndrome (a type of graft- versus-host disease). Two plasmapheresis sessions and Ig (0.5 g/kg) in combination with increased maintenance immunosuppression with a short course of oral methylprednisolone in a total dose of 150 mg during 12 days were effective. The patient was discharged from hospital 34 days after transplantation in a satisfactory condition with a stable hemoglobin level. 

трансплантация печенианемияреакция «трансплантат против хозяина»liver transplantationanemiagraft-versus-host diseaseReferencesMaruyama S. Red blood cell status in alcoholic and non-alcoholic liver disease // J. Lab. Clin. Med. 2001; 138 (5): 332–337.Maruyama S. Red blood cell status in alcoholic and non-alcoholic liver disease // J. Lab. Clin. Med. 2001; 138 (5): 332–337.Misra S. Profile of anemia in children after liver trans- plantation // Transplantation. 2000; 70 (10): 1459–1463.Misra S. Profile of anemia in children after liver trans- plantation // Transplantation. 2000; 70 (10): 1459–1463.Randomised trial comparing tacrolimus (FK506) and cy- closporin in prevention of liver allograft rejection // Eu- ropean FK506 Multicentre Liver Study Group. Lancet.Randomised trial comparing tacrolimus (FK506) and cy- closporin in prevention of liver allograft rejection // Eu- ropean FK506 Multicentre Liver Study Group. Lancet.; 344 (8920): 423–428.; 344 (8920): 423–428.Wiesner R. A randomized double-blind comparative studyWiesner R. A randomized double-blind comparative studyof mycophenolate mofetil and azathioprine in combinati- on with cyclosporine and corticosteroids in primary liver transplant recipients // Liver Transpl. 2001; 7 (5): 442–450.of mycophenolate mofetil and azathioprine in combinati- on with cyclosporine and corticosteroids in primary liver transplant recipients // Liver Transpl. 2001; 7 (5): 442–450.Maheshwari A., Mishra R., Thuluvath P.J. Post-liver- transplant anemia: etiology and management // Liver Transpl. 2004; 10 (2): 165–173.Maheshwari A., Mishra R., Thuluvath P.J. Post-liver- transplant anemia: etiology and management // Liver Transpl. 2004; 10 (2): 165–173.Yazer M.H., Triulzi D.J. Immune hemolysis following AB0-mismatched stem cell or solid organ transplantati- on // Curr. Opin. Hematol. 2007; 14 (6): 664–670.Yazer M.H., Triulzi D.J. Immune hemolysis following AB0-mismatched stem cell or solid organ transplantati- on // Curr. Opin. Hematol. 2007; 14 (6): 664–670.Shortt J. A ‘dangerous’ group 0 donor: severe hemolysis in all recipients of organs from a donor with multiple red cell alloantibodies // Am. J. Transplant. 2008; 8 (3): 711–714.Shortt J. A ‘dangerous’ group 0 donor: severe hemolysis in all recipients of organs from a donor with multiple red cell alloantibodies // Am. J. Transplant. 2008; 8 (3): 711–714.Seltsam A. Donor-derived alloantibodies and passenger lymphocyte syndrome in two of four patients who recei- ved different organs from the same donor // Transfusion. 2001; 41 (3): 365–370.Seltsam A. Donor-derived alloantibodies and passenger lymphocyte syndrome in two of four patients who recei- ved different organs from the same donor // Transfusion. 2001; 41 (3): 365–370.Salerno C.T. Donor-derived antibodies and hemolysis after ABO-compatible but nonidentical heart-lung and lung transplantation // Transplantation. 1998; 65 (2): 261–264.Salerno C.T. Donor-derived antibodies and hemolysis after ABO-compatible but nonidentical heart-lung and lung transplantation // Transplantation. 1998; 65 (2): 261–264.Panaro F. Severe hemolytic anemia due to passenger lymphocytes after living-related bowel transplant // Clin. Transplant. 2004; 18 (3): 332–335.Panaro F. Severe hemolytic anemia due to passenger lymphocytes after living-related bowel transplant // Clin. Transplant. 2004; 18 (3): 332–335.Sokol R.J. Posttransplant immune-mediated hemolysis // Transfusion. 2002; 42 (2): 198–204.Sokol R.J. Posttransplant immune-mediated hemolysis // Transfusion. 2002; 42 (2): 198–204.Berenguer M. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppressi- on // J. Hepatol. 2006; 44 (4): 717–722.Berenguer M. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppressi- on // J. Hepatol. 2006; 44 (4): 717–722.Humar A. Steroid minimization in liver transplant re- cipients: impact on hepatitis C recurrence and post- transplant diabetes // Clin. Transplant. 2007; 21 (4): 526–531.Humar A. Steroid minimization in liver transplant re- cipients: impact on hepatitis C recurrence and post- transplant diabetes // Clin. Transplant. 2007; 21 (4): 526–531.Lefaucheur C. Comparison of combination Plasmaphe- resis/IVIg/anti-CD20 versus high-dose IVIg in the treat- ment of antibody-mediated rejection // Am. J. Transplant. 2009; 9 (5): 1099–1107.Lefaucheur C. Comparison of combination Plasmaphe- resis/IVIg/anti-CD20 versus high-dose IVIg in the treat- ment of antibody-mediated rejection // Am. J. Transplant. 2009; 9 (5): 1099–1107.Bartel G., Schwaiger E., Bohmig G.A. Prevention and treatment of alloantibody-mediated kidney transplant re- jection // Transpl. Int. 2011; 24 (12): 1142–1155.Bartel G., Schwaiger E., Bohmig G.A. Prevention and treatment of alloantibody-mediated kidney transplant re- jection // Transpl. Int. 2011; 24 (12): 1142–1155.Marfo K. Desensitization protocols and their outcome // Clin. J. Am. Soc. Nephrol. 2011; 6 (4): 922–936.Marfo K. Desensitization protocols and their outcome // Clin. J. Am. Soc. Nephrol. 2011; 6 (4): 922–936.Jordan S.C. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation // Trans. Am. Clin. Climatol. Assoc. 2006; 117: 199–211; discussion 211.Jordan S.C. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation // Trans. Am. Clin. Climatol. Assoc. 2006; 117: 199–211; discussion 211.Lee H.J. Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Trans- plant. 2008; 42 (1): 67–69.Lee H.J. Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Trans- plant. 2008; 42 (1): 67–69.Hoffman P.C. Immune hemolytic anemia-selected to- pics // Hematology Am. Soc. Hematol. Educ. Program. 2006: 13–18.Hoffman P.C. Immune hemolytic anemia-selected to- pics // Hematology Am. Soc. Hematol. Educ. Program. 2006: 13–18.

The authors declare that there are no conflicts of interest present.